{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:56:31Z","timestamp":1746320191676},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10637-020-00902-9","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T02:02:34Z","timestamp":1579658554000},"page":"1598-1600","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia"],"prefix":"10.1007","volume":"38","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"902_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120:538\u2013551","journal-title":"Blood"},{"key":"902_CR2","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4065\/80.12.1660","volume":"80","author":"F Ravandi","year":"2005","unstructured":"Ravandi F, O'brien S (2005) Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 80:1660\u20131674","journal-title":"Mayo Clin Proc"},{"key":"902_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","volume":"20","author":"I Del Giudice","year":"2006","unstructured":"Del Giudice I, Davis Z, Matutes E et al (2006) IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia. 20:1231\u20131237","journal-title":"Leukemia."},{"key":"902_CR4","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, O'Brien SM, Wierda WG et al (2015) Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612\u20133621","journal-title":"Cancer."},{"key":"902_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1365-2141.1979.tb01159.x","volume":"42","author":"R Sibbald","year":"1979","unstructured":"Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy---CHOP. Br J Haematol 42:488\u2013490","journal-title":"Br J Haematol"},{"key":"902_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JCO.1997.15.1.37","volume":"15","author":"A Saven","year":"1997","unstructured":"Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L (1997) Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 15:37\u201343","journal-title":"J Clin Oncol"},{"key":"902_CR7","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1038\/oncsis.2013.30","volume":"2","author":"M Hashimoto","year":"2013","unstructured":"Hashimoto M, Suizu F, Tokuyama W et al (2013) Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo. Oncogenesis. 2:e70","journal-title":"Oncogenesis."},{"key":"902_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/bjh.14066","volume":"177","author":"TA Eyre","year":"2017","unstructured":"Eyre TA, Fox CP, Shankara P, Went R, Schuh AH (2017) Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia. Br J Haematol 177:486\u2013491","journal-title":"Br J Haematol"},{"key":"902_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","volume":"113","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr (2016) Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res 113:395\u2013408","journal-title":"Pharmacol Res"},{"key":"902_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fon.14.51","volume":"10","author":"MS Davids","year":"2014","unstructured":"Davids MS, Brown JR (2014) Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol 10:957\u2013967","journal-title":"Future Oncol"},{"key":"902_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.14224","volume":"179","author":"MJ Gordon","year":"2017","unstructured":"Gordon MJ, Raess PW, Young K, Spurgeon SEF, Danilov AV (2017) Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol 179:501\u2013503","journal-title":"Br J Haematol"},{"key":"902_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/10428194.2017.1347653","volume":"59","author":"M Damlaj","year":"2018","unstructured":"Damlaj M, Al Balwi M, Al Mugairi AM (2018) Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. Leuk Lymphoma. 59:739\u2013742","journal-title":"Leuk Lymphoma."},{"key":"902_CR13","first-page":"8563218","volume":"2017","author":"H Coelho","year":"2017","unstructured":"Coelho H, Badior M, Melo T (2017) Sequential kinase inhibition (Idelalisib\/Ibrutinib) induces clinical remission in B-cell Prolymphocytic leukemia harboring a 17p deletion. Case Rep Hematol 2017:8563218","journal-title":"Case Rep Hematol"},{"key":"902_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00277-008-0541-5","volume":"88","author":"A Tempescul","year":"2009","unstructured":"Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, le Bris MJ, de Braekeleer M, Berthou C (2009) A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol 88:85\u201388","journal-title":"Ann Hematol"},{"key":"902_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","volume":"87","author":"KU Chow","year":"2011","unstructured":"Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L (2011) Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 87:426\u2013433","journal-title":"Eur J Haematol"},{"key":"902_CR16","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1080\/10428190903166330","volume":"50","author":"R Weide","year":"2009","unstructured":"Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, K\u00f6ppler H (2009) Bendamustine\/mitoxantrone\/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 50:1468\u20131474","journal-title":"Leuk Lymphoma"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00902-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:44:44Z","timestamp":1678509884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00902-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["902"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00902-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Satoko Oka declares that she has no conflict of interest. Kazuo Ono declares that he has no conflict of interest. Masaharu Nohgawa declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}